Oncology Division
Alphabetical list (active faculty):   
Mia C. Weiss

Mia C. Weiss, MD

Assistant Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Bone and soft tissue sarcoma

Research Interests

  • Clinical trials in soft tissue and bone sarcoma
  • Precision medicine and genomics
  • Sarcoma in older adults


  • 314-747-3096 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Room 11310, Mid Campus Center (office)


As a medical oncologist my career is dedicated to the care of patients with soft tissue and bone sarcomas. I am developing clinical trials to study novel targeted therapies in this patient population and to elucidate the reasons why some patients respond to targeted therapy while others do not. In addition, given my particular interest in geriatrics, I am looking at ways to optimize care for older adults with bone and soft tissue sarcoma, and to utilize genomic sequencing to establish clinical trials specifically for this patient population for which therapeutic options can often be limited.

I serve currently as Site Principal Investigator on several clinical trials in medical oncology:

  • a.     201801202: A Phase IB Trial Of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS)
  • b.     201904129: A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-Targeting Human Antibody-Cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-Line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
  • c.     201911176: A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
  • d.     202001168: A Phase 2, Single-Arm Open-Label Study of Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as having CDK Pathway Alteration
  • e.     202002113: A Phase II Study of Cabozantinib and Temozolomide in Patients with Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
  • f.      202008172: NCI Protocol 10330, A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
  • g.     202010010: Envasarc: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
  • h.     202102173: A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients with Advanced Solid Tumors
  • i.      202103092: A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients with Advanced Solid Tumors
  • j.      202108161: SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
  • k.     202112086: A dose escalation and dose expansion study of NOX66 plus doxorubicin in anthracycline-naïve, adult patients with soft tissue sarcoma - CEP-2